Based on a meta-analysis of cardiovascular outcomes in type 2 diabetes studies, the findings suggest that a 15% relative risk reduction in nonfatal myocardial infarcts is associated with an A1c reduction of approximately: Answer: B. 1.0% A meta-analysis of cardiac outcomes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE), and Veteran Affairs Diabetes Trial (VADT) found every approximate 1% A1C reduction was positively correlated with a 15% relative risk reduction for myocardial infarct. The A1C benefits did not extend to stroke or all-cause mortality. Reference(s): Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009; 52(1)2288–2298
Cardio Risk Reduction
Feb 9, 2019
Correct
Incorrect